FindTrial
Sign In

Guiding anti-HER2 targeted therapy for breast cancer patients based on HER2 expression ofcirculating tumor cell

Accurately guiding anti-HER2 targeted therapy for breast cancer patients based on circulating tumor cell dynamics and multiple dimension redefining HER2 expression

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400085187
Enrollment
Unknown
Registered
2024-06-03
Start date
2024-06-03
Completion date
Unknown
Last updated
2024-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

Anti-HER2 ADC treatment:None

Sponsors

The Fifth Medical Center of the Chinese PLA General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1) Age>18 2) Locally advanced or recurrent metastatic breast cancer patients 3)ECOG 0 or 1 4) Accurate hormone receptor and HER2 expression status 5) Patients treated with anti-HER2 ADC drugs 6) Sign informed consent

Exclusion criteria

Exclusion criteria: 1) The expected survival is less than 3 months 2) Patients with unadequate blood, liver and kidney function 3) Patients with active brain metastases 4) Pregnant and nursing patients 5) Patients who cannot be followed up

Design outcomes

Primary

MeasureTime frame
Objective response rate;Progression free survival;CTCs HER2 expression;—

Secondary

MeasureTime frame
Clinical benefit rate;—

Countries

China

Contacts

Public ContactTao Wang

The Fifth Medical Center of the Chinese PLA General Hospital

wangtao733073@163.com+86 10 6694 7250

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026